PaxMedica, Inc. financial data

Symbol
PXMD on OTC
Location
303 South Broadway, Suite 125, Tarrytown, NY
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Sep 20, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 151 % -17.5%
Debt-to-equity 465 % +215%
Return On Equity -3.17K % -141%
Return On Assets -560 % -5.52%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 10.9M shares
Common Stock, Shares, Outstanding 7.78M shares -49.4%
Entity Public Float 4.1M USD
Weighted Average Number of Shares Outstanding, Basic 7.66M shares +789%
Weighted Average Number of Shares Outstanding, Diluted 7.66M shares +789%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD
Research and Development Expense 5.01M USD +264%
General and Administrative Expense 10.4M USD -23.8%
Operating Income (Loss) -15.4M USD -2.47%
Nonoperating Income (Expense) -2.35M USD +70.1%
Net Income (Loss) Attributable to Parent -17.7M USD +26.4%
Earnings Per Share, Basic -2.68 USD/shares +93%
Earnings Per Share, Diluted -2.68 USD/shares +92.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.99M USD
Accounts Receivable, after Allowance for Credit Loss, Current 500K USD
Assets, Current 800K USD -84.5%
Assets 800K USD -84.5%
Accounts Payable, Current 2.04M USD
Employee-related Liabilities, Current 873K USD +71.1%
Accrued Liabilities, Current 965K USD -5.3%
Liabilities, Current 2.11M USD -13.1%
Liabilities 2.61M USD -9.44%
Retained Earnings (Accumulated Deficit) -58.7M USD -43%
Stockholders' Equity Attributable to Parent -1.81M USD -180%
Liabilities and Equity 800K USD -84.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.07M USD -2.85%
Net Cash Provided by (Used in) Financing Activities -15.3K USD -100%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 7.78M shares -49.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 324K USD -89.4%
Deferred Tax Assets, Valuation Allowance 7.21M USD +49.2%
Deferred Tax Assets, Gross 7.21M USD +49.2%
Deferred Tax Assets, Operating Loss Carryforwards 5.41M USD +46.8%
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 56.9M USD +31.4%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 1.51M USD -30.3%
Interest Expense 9.17K USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%